Stefano Rusconi to Oxazines
This is a "connection" page, showing publications Stefano Rusconi has written about Oxazines.
Connection Strength
0.276
-
Long-term data on the efficacy and tolerability of lamivudine plus dolutegravir as a switch strategy in a multi-centre cohort of HIV-1-infected, virologically suppressed patients. Int J Antimicrob Agents. 2019 Dec; 54(6):728-734.
Score: 0.043
-
Durability of first-line regimens including integrase strand transfer inhibitors (INSTIs): data from a real-life setting. J Antimicrob Chemother. 2019 05 01; 74(5):1363-1367.
Score: 0.042
-
Durability of dolutegravir plus boosted darunavir as salvage or simplification of salvage regimens in HIV-1 infected, highly treatment-experienced subjects. HIV Clin Trials. 2018 12; 19(6):242-248.
Score: 0.041
-
Dolutegravir Plus Rilpivirine as a Switch Option in cART-Experienced Patients: 96-Week Data. Ann Pharmacother. 2018 08; 52(8):740-746.
Score: 0.039
-
A dual regimen of ritonavir/darunavir plus dolutegravir for rescue or simplification of rescue therapy: 48 weeks' observational data. BMC Infect Dis. 2017 09 30; 17(1):658.
Score: 0.038
-
Discontinuation of treatment and adverse events in an Italian cohort of patients on dolutegravir. AIDS. 2017 01 28; 31(3):455-457.
Score: 0.036
-
Efficacy and tolerability of dolutegravir and two nucleos(t)ide reverse transcriptase inhibitors in HIV-1-positive, virologically suppressed patients. AIDS. 2017 01 28; 31(3):457-459.
Score: 0.036